GSK Corp - רווח נקי למניה (EPS TTM) GSK
GSK plc is aggressively updating its portfolio by investing in vaccine R&D and oncology. The rolling earnings per share history demonstrates financial resilience, with the current mark equal to 2.86. HIV medications provide a stable cash flow, creating a reliable revenue base. Meanwhile, the company is optimizing costs by outsourcing clinical trials and packaging to third-party contractors.
פילוחים אנליטיים של חברת GSK plc
Stable demand for GSK plc (GSK) humanitarian pharmaceuticals amid minimal geopolitical risks ensures predictable cash flow generation. This metric is calculated as the ratio of total net income to the number of shares outstanding; therefore, the 12-month earnings per share history allows for an objective assessment of the real return on capital and the determination of the asset's fair value.
